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ABSTRACT 13 
We evaluated the feasibility of 5-aminolevulinic acid (5-ALA)-mediated photodynamic diagnosis (PDD) in the biopsy 14 
for primary central nervous system lymphoma (PCNSL). 5-ALA (20 mg/kg) was administered orally 4 hours 15 
preoperatively. Forty-one biopsies obtained under PDD in 47 consecutive biopsies (46 patients) that were finally 16 
pathologically diagnosed as PCNSL were evaluated. Positive fluorescence was observed in 34 of those 41 biopsies 17 
(82.9%). An intraoperative pathological diagnosis (IOD) of suspected PCNSL was made in 21 of the biopsies with 18 
positive fluorescence (61.8%). However, the 8 IODs in the remaining 13 biopsies (23.5%) were not correct (atypical cell, 19 
4; high-grade glioma, 1; gliosis, 1; unremarkable, 2). In those 8 biopsies, PCNSL was confirmed by the final pathological 20 
diagnosis. There was no difference in the mean Mib-1 labeling index between the biopsies with positive fluorescence 21 
(86.5%) and those without (90.0%). IOD was not performed in 6 biopsies; however, 5 of those biopsies (83.3%) showed 22 
positive fluorescence and were finally pathologically diagnosed as PCNSL. Use of PDD in biopsies for patients with 23 
suspected PCNSL is a reliable way of obtaining specimens of adequate quality for the final pathological diagnosis and 24 
may lead to improved diagnostic yield in the biopsy of PCNSL. 25 
26 
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Introduction 32 
Photodynamic diagnosis (PDD) in neurosurgery for several types of brain tumors was first described by Moore and 33 
colleagues [1]. While the PDD in their study was predominantly mediated by fluorescein, 5-aminolevulinic acid (5-ALA) 34 
has been successfully applied for fluorescence-guided tumor resections, leading to the widespread use of this technique 35 
in the neurosurgical field worldwide. In 5-ALA-mediated PDD, fluorescence is obtained on the basis of accumulation of 36 
protoporphyrin IX (PpIX) in malignant tumor cells following oral administration of 5-ALA as a precursor of heme 37 
biosynthesis. Proof of the benefit of 5-ALA-mediated PDD for glioblastoma was obtained by a randomized controlled 38 
multicenter phase-III trial conducted by Stummer and colleagues, which showed statistically significant improvement in 39 
the extent of tumor removal and 6-month progression-free survival after surgery, although the overall survival was not 40 
prolonged [2]. 41 
42 
PDD using 5-ALA has also been applied in surgery for brain tumors other than glioblastomas, such as meningiomas, 43 
pituitary adenomas, and metastatic tumors [3-5]. For instance, 94.0% (31 of 33) of meningiomas showed positive 44 
fluorescence [3]. The sensitivity of 5-ALA-mediated PDD for pituitary adenoma was 80.8% (21/26) in endoscopy with 45 
photodiagnostic filters and 95.5% (21/22) in the PpIX spectroscopy optical biopsy system [4]. Fifty-two of 78 pediatric 46 
brain tumors (66.7%) showed positive fluorescence; they included high-grade gliomas (HGG), ependymomas, primitive 47 
neuroectodermal tumors (PNETs), gangliogliomas, medulloblastomas, and pilocytic astrocytomas [6]. 48 
49 
Biopsy and subsequent pathologic confirmation are undertaken as the standard of care for PCNSL such as systemic 50 
4 
4 
chemotherapy and radiotherapy. However, only a few PCNSL cases have previously been reported (a portion of a patient 51 
cohort who received 5-ALA-mediated PDD), and the role and impact of PDD for PCNSL have not been established. 52 
Minimizing the extent of surgery is essential for reducing the risks during brain tumor biopsies, while samples that are 53 
adequate in number and quality are required to ensure the final pathological diagnosis. To evaluate the feasibility of PDD 54 
during the biopsy strategy for PCNSL, we studied the rate of positive fluorescence and the relation between PDD and the 55 
pathologic diagnosis of PCNSL. 56 
57 
Patients and methods 58 
This was a retrospective study on a portion of the data obtained from an institutional review board-approved 59 
prospective study on PDD for intraparenchymal brain tumors (no. 89). The data collection included the preoperative 60 
neuroradiologic diagnosis, PDD, intraoperative pathologic diagnosis (IOD), and final pathologic diagnosis. Forty-six 61 
consecutive patients with a final pathologic diagnosis of PCNSL received 47 biopsies (open biopsy, 27; 62 
navigation-guided endoscopic biopsy, 14; stereotactic biopsy, 6) at the University of Tsukuba Hospital between July 2003 63 
and December 2013. Of those 47 biopsies, 41 were obtained under PDD and were included in this study. In the other 6 64 
biopsies, PDD was omitted owing to the need for emergency surgery. In all 47 biopsies, the preoperative neuroradiologic 65 
diagnosis was PCNSL. 66 
67 
>Figures 1 and 2< 68 
69 
5 
5 
70 
5-ALA (20 mg/kg; Cosmo Bio, Tokyo, Japan) was administered orally 4 hours preoperatively. After induction of 71 
general anesthesia, the patient’s head was fixed using a Mayfield or Sugita frame, and the navigation system 72 
(StealthStation; Medtronic, USA.) was set up. For the endoscopic biopsies, a transparent sheath (7 or 10 mm in diameter) 73 
with a removable inner tube (Neuroport; Olympus, Tokyo, Japan) was inserted through the burr hole until the front of the 74 
target lesion was under the control of the navigation system; the lesion was further observed with a rigid endoscope 75 
(EndoArm; Olympus). In the endoscopic biopsies, the lesion was gradually removed [7]. Open biopsy was also 76 
performed under navigation-guided planning. After the skin incision and small craniotomy, a 12-Fr catheter tube was 77 
inserted from the brain surface towards the target, and a 1.5- to 2-cm corticotomy, performed. In the stereotactic biopsies, 78 
a Komai stereotactic frame or frameless neuronavigation was used, and the first target was set at the central or 79 
near-central region of the enhanced mass, and 4 or more samples were collected around the first target and periphery of 80 
the tumor for further pathologic diagnosis (Figs. 1 and 2). Samples were collected from at least 2 different biopsy targets, 81 
and those with positive fluorescence were sent to the pathology department for IOD. If suspected PCNSL was diagnosed, 82 
the remaining samples were kept for the final pathologic diagnosis. If IOD did not point to a diagnosis of suspected 83 
PCNSL or if there were no samples with positive fluorescence, additional sample collection was decided upon by each 84 
surgeon according to the potential risk in each case. The rates of positive fluorescence (strong or weak according to the 85 
macroscopic observations) and the relation between PDD and the pathologic diagnosis were analyzed. 86 
87 
Results 88 
6 
6 
The final pathologic diagnosis was PCNSL (diffuse large B-cell lymphoma) for all biopsies except for 1 failed 89 
endoscopic biopsy after which the patient underwent an open biopsy and received a diagnosis of PCNSL. In 1 patient 90 
who underwent repeated biopsies and who received corticosteroids during a previous hospitalization at another hospital, 91 
the specimen obtained at the first biopsy showed weak fluorescence in the tissue suspected at the IOD as being 92 
lymphoma cells. However, the final pathologic diagnosis after the first biopsy could not definitely confirm that it was 93 
lymphoma tissue despite the presence of a few lymphocytes. Two weeks later, at the second biopsy, the surgical specimen 94 
was strongly fluorescent, and PCNSL was pathologically diagnosed. 95 
96 
>Figures 3 and 4< 97 
98 
Positive fluorescence was observed in 34 of the 41 biopsies conducted under PDD (82.9%; Fig. 3). Strong 99 
fluorescence was observed in 23 of those biopsies (56.1%), and weak fluorescence, in 11 of them (26.8%; Fig. 4). In 21 100 
of the 34 biopsies (61.8%), an IOD of suspected PCNSL was made. In the remaining 13 biopsies, however, the IOD was 101 
either incorrect (atypical cell, 4; high-grade glioma, 1; gliosis, 1; unremarkable, 2) or not performed (5). Thus, for all 34 102 
cases, PCNSL was diagnosed at the final pathologic examination. Intraoperative diagnosis was not conducted in 6 of the 103 
41 biopsies obtained under PDD. Five of them (83.3%) showed positive fluorescence and were diagnosed as PCNSL at 104 
the final pathologic diagnosis. Fluorescence was not observed in 7 of the 41 biopsies conducted under PDD (17.1%). In 3 105 
of those (42.9%), an IOD of suspected PCNSL was made. In the remaining 4 biopsies (57.1%), the IOD was either 106 
incorrect (atypical cell, 1; high-grade glioma, 1; necrosis, 1) or not performed (1). There was no difference in the mean 107 
7 
7 
Mib-1 labeling index between the tumor cells with positive fluorescence (86.5%) and those without (90.0%). 108 
109 
Discussion 110 
5-ALA-mediated PDD has often been performed with tumor biopsy, and such a combination is advantageous 111 
in facilitating diagnostic yield by distinguishing tumor-containing samples by use of fluorescence [7]. Although several 112 
pathologic types of brain tumor were reported in the literature on fluorescence-assisted biopsy, it is difficult to estimate 113 
the rate of positive fluorescence in PDD of PCNSL because of the limited number of such published cases. To the best of 114 
our knowledge, only 11 PCNSL cases with biopsy or resection conducted under 5-ALA-mediated PDD have been 115 
reported, and all of those showed positive fluorescence [4, 8-10]. Moriuchi and colleagues reported stereotactic biopsy 116 
conducted under PDD for a PCNSL of the thalamus and for a pontine glioma to confirm the target tumor tissues [9]. 117 
Grossman and colleagues reported positive fluorescence in PCNSL of the fourth ventricular floor [8]. Eljamel and 118 
colleagues reported 2 PCNSL with positive fluorescence [11]. Widhalm and colleagues found that all 16 samples taken 119 
from 7 PCNSL cases showed positive fluorescence (strong, 14: weak, 2) [10]. In the present study, positive fluorescence 120 
was observed in 34 of the 41 biopsies (82.9%), which is consistent with the findings of our previous biopsy report on 59 121 
intraaxial tumor cases, which showed that 9 of the 12 PCNSL cases (75%) showed positive fluorescence [7]. 122 
123 
According to a recent review, fluorescence is observed in HGG patients with 91% sensitivity and 59% 124 
specificity [12]. To date, the rate of positive fluorescence and the diagnostic yield of PDD for PCNSL have not been 125 
established. This report is the first on a large series to confirm a relatively high (82.9%) fluorescence-positive rate in 126 
8 
8 
intraoperative PDD for PCNSL. 5-ALA is metabolized intracellularly by tumor cells to form the fluorescent molecules of 127 
PpIX after passing through the intact blood-brain barrier [13]. Although the mechanism of fluorescence in lymphoma 128 
tissue is not fully understood, it has been reported that a proton-coupled folate transporter (the membrane transporter of 129 
the folate analog methotorexate in lymphoma cells) also acts as a transporter of 5-ALA [14, 15]. Some reports have 130 
indicated the correlation between the Mib-1-labeling index in glioma tissue and PDD fluorescence [16, 17]. However, 131 
more than 90% of the tumors showed a high (>80%) Mib-1 labeling index in this series, and no relation was found 132 
between the labeling index and positive fluorescence in PDD. 133 
134 
>Figure 5< 135 
>Figure 6< 136 
137 
138 
In biopsies of intraparenchymal tumors with a preoperative neuroradiologic diagnosis of suspected PCNSL, 139 
the number of samples obtainable per operation is limited to avoid postoperative complications. Therefore, it is useful 140 
that the positive fluorescence in PDD suggests a high probability of lymphoma tissue in the samples collected. Given that 141 
IOD is not routinely recommended, the application of 5-ALA PDD in brain tumor biopsies may be used to select cases 142 
that require IOD; ie, those in which only vague or no fluorescence is observed [10]. 143 
144 
However, we observed fluorescence in some specimens that did not contain or contained a very limited 145 
9 
9 
number of CD20-positive lymphoma cells (Fig. 5). It is known that the glial response, macrophages, and reactive 146 
lymphocytic infiltrates are commonly found in brain tissue adjacent to the periphery of PCNSL [18]. Importantly, in 147 
clinical and laboratory investigations, positive fluorescence was related not only to the tumor tissue but also to the 148 
inflammatory cells, reactive astrocytes, gliosis, or the interstitial bulk flow of PpIX from the fluorescence-positive tissue 149 
[19, 20]. The limitation of our report is the lack of a comparison with fluorescence-negative specimens, owing to the risk 150 
of postoperative neurologic deficits that might result from collecting fluorescence-negative tissue, especially in the tumor 151 
border or in normal tissue. According to the diagnostic reliability of positive and negative fluorescence of PDD in this 152 
series, the true-positive and false-negative rate was 34/41 (82.9%) and 7/41 (17.1%), respectively. Although random 153 
biopsy specimens from healthy brain tissue as well as from tumor tissue are required to determine true specificity and 154 
sensitivity in conjunction with PDD, we did not collect such specimens in this study. In PDD, a positive fluorescence rate 155 
is highly influenced by the diagnostic systems used, ie, photosensitizers, light source, charge-coupled device (CCD) 156 
camera, measurement devices, and filters. The fluorescence-positive rate in the non-fluorescence specimens in this series 157 
might have increased if the specimens had been spectroscopically analyzed. 158 
159 
In contrast to the treatment for other brain tumors, biopsy and the subsequent pathologic confirmation is 160 
undertaken as the standard of care for PCNSL and includes systemic chemotherapy with or without whole-brain 161 
radiotherapy or intrathecal chemotherapy. Recently, a potential survival advantage after debulking surgery rather than 162 
biopsy in patients with PCNSL has been reported [21]. In the German PCNSL Study Group-1 trial, a large randomized 163 
phase-III study comprising 526 patients with PCNSL, the progression-free survival and overall survival were 164 
10 
10 
significantly shorter in the biopsied patients than in the patients with subtotal or gross total resections [21]. Our results 165 
show the potential utility of PDD in the biopsy procedure or surgical removal of PCNSL. Thus, attention should be paid 166 
to the probability of positive fluorescence being unrelated to the tumor tissue in intraoperative PDD for PCNSL. There 167 
have been reports of photodynamic therapy combined with PDD using second-generation photosensitizers such as 168 
mTHPC and talaporfin sodium, those have superior quantum efficiency, phototoxicity, and depth of light penetration [22- 169 
24]. 170 
171 
CONCLUSION 172 
Positive fluorescence was observed in 34 of 41 biopsies (82.9%) obtained under photodynamic diagnosis for 173 
PCNSL. PDD offers a high probability of positive tumor tissue fluorescence in patients with PCNSL. PDD of biopsy 174 
samples in patients with suspected PCNSL is a feasible way to obtain accurate samples and may lead to improved 175 
diagnostic yield in the biopsy of PCNSL. 176 
177 
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 252 
Figure Legends  253 
Figure 1 Magnetic resonance images showing the region of the biopsy.  254 
The Gd-enhanced T1-weighted image showed a diffusely enhanced tumor mass in the subcortical white matter (left), 255 
which appeared as the superficial portion of the high-intensity region on the FLAIR image (middle). Surgical specimens 256 
were taken from the FLAIR high-intensity region without Gd-enhancement, the Gd-enhanced region, and the cerebral 257 
cortex region without abnormal intensity on the MRI image (right). 258 
 259 
Figure 2 Representative photographs of surgical specimens from the same patient as those shown in Figure 1.  260 
Upper: Surgical specimens obtained from a 71-year-old man with left parietal PCNSL. The 2 specimens shown on the 261 
right were obtained from the brain cortex, and the others, from the tumor and border regions. Lower: Positive 262 
fluorescence was observed in all but 1 specimen, which was covered by a clot. 263 
 264 
Figure 3 Profile of the 41 biopsies obtained under photodynamic diagnosis.  265 
16 
 
16 
 
PDD photodynamic diagnosis, IOD intraoperative pathological diagnosis, NE not evaluated. 266 
 267 
Figure 4 Positive fluorescence rates in 41 cases of primary central nervous system lymphoma (PCNSL). Positive 268 
fluorescence was observed in 34 of the 41 biopsies (82.9%). Strong fluorescence was found in 23 biopsies (56.1%), and 269 
weak fluorescence, in 11 biopsies (26.8%). 270 
FL fluorescence 271 
 272 
Figure 5 Representative microphotographs (x200).  273 
Upper : Specimens with hematoxylin and eosin (H&E) staining (left) and immunohistochemical staining using CD20 274 
antibody (right), showing CD20-negative lymphocytes with no nuclear atypia infiltrating the cerebral cortex. Note that 275 
this specimen with almost no B-cell lymphoma cells had positive fluorescence. Middle: Specimens from tumor tissue. 276 
H&E stain (left) and Ki-67 stain (right), showing the typical angiocentric infiltration pattern of PCNSL cells with a 277 
Mib-1 labeling index of 80%. Lower: Tumor cells expressed the pan-B-cell markers CD20 (left) and CD79a (right).  278 
 279 
Figure 6 Representative photograph of fluorescence of the specimen from tumor tissue. 280 
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